Riassunto
Oltre a radionuclidi gamma-emittenti, sono utilizzati per uso diagnostico anche composti che decadono mediante emissione di positroni (β+) dal nucleo. La peculiarità cui è legato l’impiego in medicina nucleare di questi nuclei radioattivi è costituita dalla radiazione che origina dall’evento di annichilazione fra particella β+ e particella β−, che avviene dopo un certo percorso nella materia (denominato positron range), rispetto al punto esatto di emissione del β+ stesso. Questa radiazione comporta l’emissione contemporanea di due raggi γ ad alta energia (511 keV) che si dipartono dal punto di annichilazione con un angolo di circa 180°, caratteristica che costituisce la base del principio fisico della rivelazione adottata in tomografia mediante emissione di positroni (PET) (vedi Capitolo 12).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Letture consigliate
Apolo AB, Pandit-Taskar N, Morris M (2008) Novel tracers and their development for the imaging of metastatic prostate cancer. J Nucl Med 49:2031–2041
Bading JR, Shields AF (2008) Imaging of cell proliferation: status and prospects. J Nucl Med 49:64S–80S
Blankenberg FG (2008) In Vivo detection of apoptosis. J Nucl Med 49:81S–95S
Cai W, Chen X (2008) Multimodality molecular imaging of tumor angiogenesis. J Nucl Med 49:113S–128S
Couturier O, Luxen A, Chatal JF (2004) Fluorinated tracers for imaging cancer with positron emission tomography. 31(8):1182–1206
Dunphy MP, Lewis JS (2009) Radiopharmaceuticals in preclinical and clinical development for monitoring of therapy with PET. J Nucl Med 50:106S–121S
Ell PJ, Gambhir SS (eds) (2004) Nuclear Medicine in Clinical Diagnosis and Treatment, 3rd edn. Churchill Livingston, New York
Fanti S, Ambrosini V, Tomassetti P et al (2008) Evaluation of unusual neuroendocrine tumours by means of 68Ga-DOTA-NOC PET. Biomed Pharmacother 62:667–671
Ghesani M, Depuey EG, Rozanski A (2005) Role of F-18 FDG Positron Emission Tomography (PET) in the assessment of myocardial viability. Echocardiography 22:165–177
Harbert JC, Eckelman WC, Neumann RD (eds) (1996) Nuclear Medicine — Diagnosis and Therapy. Thieme Medical Publishers, New York
Hospers G, Helmond FA, de Vries EG et al (2008) PET imaging of steroid receptor expression in breast and prostate cancer. Curr Pharm Des 14:3020–3032
Jacobs AH, Thomas A, Kracht LW et al (2005) 18F-fluoro-L-thymidine and 11C-methylmethionine as markers of increased transport and proliferation in brain tumors. J Nucl Med 46:1948–1958
Klunk WE, Mathis CA (2008) The future of amyloid-beta imaging: a tale of radionuclide and tracer proliferation. Curr Opin Neurol 21:683–687
Koeppe RA, Gilman S, Joshi A et al (2005) 11C-DTBZ and 18F-FDG PET measures in differentiating dementias. J Nucl Med 46:936–944
Kumar R, Dhanpathi H, Basu S et al (2008) Oncologic PET tracers beyond [18F]FDG and the novel quantitative approaches in PET imaging. Q J Nucl Med Mol Imaging 52:50–65
Li Y, Rinne JO, Mosconi L et al (2008) Regional analysis of FDG and PIB-PET images in normal aging, mild cognitive impairment, and Alzheimer’s disease. Eur J Nucl Med Mol Imaging 35:2169–2181
Machac J (2005) Cardiac positron emission tomography imaging. Semin Nucl Med 35:17–36
Miller P, Long N, Vilar R (2008) Synthesis of 11C, 18F, 15O, and 13N radiolabels for positron emission tomography. Angew Chem Int Ed Eng 47:8998–9033
Mishani E, Abourbeh G, Eiblmaier M et al (2008) Imaging of EGFR and EGFR tyrosine kinase overexpression in tumors by nuclear medicine modalities. Curr Pharm Des 14:2983–2998
Shiue CY, Welch MJ (2004) Update on PET radiopharmaceutical: life beyond fluorodeoxyglucose. Radiol Clin N Am 42:1033–1053
Vallabhajosula S (2007) 18F-labeled positron emission tomographic radiopharmaceuticals in oncology: an overview of radiochemistry and mechanisms of tumor localization. Semin Nucl Med 37:400–419
Vallabhajosula S (2009) Molecular Imaging — Radiopharmaceuticals for PET and SPECT. Springer, New York
Visser FC (2001) Imaging of cardiac metabolism using radiolabelled glucose, fatty acids and acetate. Coron Artery Dis 12:S12–S18
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer-Verlag Italia
About this chapter
Cite this chapter
Lorenzoni, A., Orsini, F., Salvadori, P.A. (2010). Radiofarmaci per tomografia a emissione di positroni. In: Volterrani, D., Mariani, G., Erba, P.A. (eds) Fondamenti di medicina nucleare. Springer, Milano. https://doi.org/10.1007/978-88-470-1685-9_5
Download citation
DOI: https://doi.org/10.1007/978-88-470-1685-9_5
Publisher Name: Springer, Milano
Print ISBN: 978-88-470-1684-2
Online ISBN: 978-88-470-1685-9
eBook Packages: MedicineMedicine (R0)